191 related articles for article (PubMed ID: 33737034)
1. Randomized, Double-Masked, Pilot Study of Netarsudil 0.02% Ophthalmic Solution for Treatment of Corneal Edema in Fuchs Dystrophy.
Price MO; Price FW
Am J Ophthalmol; 2021 Jul; 227():100-105. PubMed ID: 33737034
[TBL] [Abstract][Full Text] [Related]
2. Hyperosmolar Eye Drops for Diurnal Corneal Edema in Fuchs' Endothelial Dystrophy: A Double-Masked, Randomized Controlled Trial.
Zander DB; Böhringer D; Fritz M; Grewing V; Maier PC; Lapp T; Reinhard T; Wacker K
Ophthalmology; 2021 Nov; 128(11):1527-1533. PubMed ID: 33892048
[TBL] [Abstract][Full Text] [Related]
3. Pilot Study of Corneal Clearance With the Use of a Rho-Kinase Inhibitor After Descemetorhexis Without Endothelial Keratoplasty for Fuchs Endothelial Corneal Dystrophy.
Davies E; Jurkunas U; Pineda R
Cornea; 2021 Jul; 40(7):899-902. PubMed ID: 33758139
[TBL] [Abstract][Full Text] [Related]
4. Descemet Stripping Only Supplemented With Topical Ripasudil for Fuchs Endothelial Dystrophy 12-Month Outcomes of the Sydney Eye Hospital Study.
Moloney G; Garcerant Congote D; Hirnschall N; Arsiwalla T; Luiza Mylla Boso A; Toalster N; D'Souza M; Devasahayam RN
Cornea; 2021 Mar; 40(3):320-326. PubMed ID: 32740006
[TBL] [Abstract][Full Text] [Related]
5. A Close Look at the Clinical Efficacy of Rho-Associated Protein Kinase Inhibitor Eye Drops for Fuchs Endothelial Corneal Dystrophy.
Kinoshita S; Colby KA; Kruse FE
Cornea; 2021 Oct; 40(10):1225-1228. PubMed ID: 34481406
[TBL] [Abstract][Full Text] [Related]
6. Phase 2, Randomized, Open-Label Parallel-Group Study of Two Dosing Regimens of Netarsudil for the Treatment of Corneal Edema Due to Fuchs Corneal Dystrophy.
Lindstrom RL; Lewis AE; Holland EJ; Sheppard JD; Hovanesian JA; Senchyna M; Hollander DA
J Ocul Pharmacol Ther; 2022 Dec; 38(10):657-663. PubMed ID: 36327101
[No Abstract] [Full Text] [Related]
7. Rho kinase (ROCK) inhibitors in the management of corneal endothelial disease.
Syed ZA; Rapuano CJ
Curr Opin Ophthalmol; 2021 May; 32(3):268-274. PubMed ID: 33606407
[TBL] [Abstract][Full Text] [Related]
8. Case Series: Novel Utilization of Rho-Kinase Inhibitor for the Treatment of Corneal Edema.
Davies E
Cornea; 2021 Jan; 40(1):116-120. PubMed ID: 33269892
[TBL] [Abstract][Full Text] [Related]
9. Descemetorhexis Without Grafting for Fuchs Endothelial Dystrophy-Supplementation With Topical Ripasudil.
Moloney G; Petsoglou C; Ball M; Kerdraon Y; Höllhumer R; Spiteri N; Beheregaray S; Hampson J; DʼSouza M; Devasahayam RN
Cornea; 2017 Jun; 36(6):642-648. PubMed ID: 28476048
[TBL] [Abstract][Full Text] [Related]
10. Transient Reticular Cystic Corneal Epithelial Edema With Topical Netarsudil: A Case Series and Review.
LoBue SA; Moustafa GA; Vu A; Amin M; Nguyen T; Goyal H
Cornea; 2021 Aug; 40(8):1048-1054. PubMed ID: 33369939
[TBL] [Abstract][Full Text] [Related]
11. Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2).
Kahook MY; Serle JB; Mah FS; Kim T; Raizman MB; Heah T; Ramirez-Davis N; Kopczynski CC; Usner DW; Novack GD;
Am J Ophthalmol; 2019 Apr; 200():130-137. PubMed ID: 30653957
[TBL] [Abstract][Full Text] [Related]
12. Rho-associated kinase inhibitor eye drop treatment as a possible medical treatment for Fuchs corneal dystrophy.
Koizumi N; Okumura N; Ueno M; Nakagawa H; Hamuro J; Kinoshita S
Cornea; 2013 Aug; 32(8):1167-70. PubMed ID: 23715376
[TBL] [Abstract][Full Text] [Related]
13. Re: Zander et al.: Hyperosmolar eye drops for diurnal corneal edema in Fuchs' endothelial dystrophy: a double-masked randomized controlled trial (Ophthalmology. 2021;128:1527-1533).
Hoffart L
Ophthalmology; 2022 Sep; 129(9):e84. PubMed ID: 35623916
[No Abstract] [Full Text] [Related]
14. Reticular Bullous Epithelial Edema in Corneas Treated with Netarsudil: A Case Series.
Wisely CE; Liu KC; Gupta D; Carlson AN; Asrani SG; Kim T
Am J Ophthalmol; 2020 Sep; 217():20-26. PubMed ID: 32289295
[TBL] [Abstract][Full Text] [Related]
15. Netarsudil Improves Trabecular Outflow Facility in Patients with Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 2 Study.
Sit AJ; Gupta D; Kazemi A; McKee H; Challa P; Liu KC; Lopez J; Kopczynski C; Heah T
Am J Ophthalmol; 2021 Jun; 226():262-269. PubMed ID: 33524367
[TBL] [Abstract][Full Text] [Related]
16. Quality of vision in patients with fuchs endothelial dystrophy and after descemet stripping endothelial keratoplasty.
van der Meulen IJ; Patel SV; Lapid-Gortzak R; Nieuwendaal CP; McLaren JW; van den Berg TJ
Arch Ophthalmol; 2011 Dec; 129(12):1537-42. PubMed ID: 21825178
[TBL] [Abstract][Full Text] [Related]
17. New therapeutic modality for corneal endothelial disease using Rho-associated kinase inhibitor eye drops.
Koizumi N; Okumura N; Ueno M; Kinoshita S
Cornea; 2014 Nov; 33 Suppl 11():S25-31. PubMed ID: 25289721
[TBL] [Abstract][Full Text] [Related]
18. Cataract surgery in patients with Fuchs' corneal dystrophy: expanding recommendations for cataract surgery without simultaneous keratoplasty.
Seitzman GD; Gottsch JD; Stark WJ
Ophthalmology; 2005 Mar; 112(3):441-6. PubMed ID: 15745771
[TBL] [Abstract][Full Text] [Related]
19. Diurnal Variation in Corneal Edema in Fuchs Endothelial Corneal Dystrophy.
Fritz M; Grewing V; Maier P; Lapp T; Böhringer D; Reinhard T; Wacker K
Am J Ophthalmol; 2019 Nov; 207():351-355. PubMed ID: 31415734
[TBL] [Abstract][Full Text] [Related]
20. Randomized, Double-Masked Trial of Netarsudil 0.02% Ophthalmic Solution for Prevention of Corticosteroid-Induced Ocular Hypertension.
Price MO; Feng MT; Price FW
Am J Ophthalmol; 2021 Feb; 222():382-387. PubMed ID: 33045216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
